{"title":"The Rate of Postoperative Decline in Parathyroid Hormone Levels Can Predict Symptomatic Hypocalcemia Following Thyroid Cancer Surgery with Neck Lymph Node Dissection.","authors":"Yi-Hsuan Lee, Zhijian Liu, LuLu Zheng, Junlan Qiu, Jianfeng Sang, Wenxian Guan","doi":"10.1080/01635581.2024.2401179","DOIUrl":"10.1080/01635581.2024.2401179","url":null,"abstract":"<p><strong>Objective: </strong>Identifying early predictive indicators of symptomatic hypocalcemia in patients after thyroidectomy with neck lymph node dissection can help to identify high-risk patients, provide timely intervention, and improve prognosis.</p><p><strong>Methods: </strong>A retrospective analysis of all relevant information was conducted for patients who underwent total thyroidectomy with neck lymph node dissection at our hospital between April 2021 and September 2022. The primary outcome measure was symptomatic hypocalcemia.</p><p><strong>Results: </strong>Of the 210 patients who underwent total thyroidectomy with l neck lymph node dissection, 76 patients (36%) experienced symptoms of hypocalcemia. The analysis confirmed that the rate of parathyroid hormone (PTH) decline (OR = 238.414, 95%CI: 51.904-1095.114, <i>P</i> = 0.000) was an independent risk factor for symptomatic hypocalcemia after total thyroidectomy with neck lymph node dissection. The ROC curve indicated that a PTH decline cutoff value of 0.7425 was significantly correlated with symptoms of hypocalcemia, with a sensitivity of 89% and specificity of 69%, which could effectively predict symptomatic hypocalcemia.</p><p><strong>Conclusion: </strong>A PTH decline rate greater than the cutoff value of 0.7425 is a predictive factor for symptomatic hypocalcemia in adults and may be considered as a high-risk patient and actively managed to supplement calcium as soon as possible to ensure patient safety.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"1-8"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142309073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xu Zhang, Wenjing Yang, Junliang Shang, Lin Shi, Lu Yang, Chi Zhang, Yuyi Chen, Zishen Liu, Bo Li, Xinghan Zhang, Li Tong, Guowang Yang
{"title":"Acupuncture's Emergence as A Promising Non-Pharmacological Therapy for Appetite Management in Cancer Chemotherapy.","authors":"Xu Zhang, Wenjing Yang, Junliang Shang, Lin Shi, Lu Yang, Chi Zhang, Yuyi Chen, Zishen Liu, Bo Li, Xinghan Zhang, Li Tong, Guowang Yang","doi":"10.1080/01635581.2024.2413717","DOIUrl":"10.1080/01635581.2024.2413717","url":null,"abstract":"<p><strong>Objective: </strong>The primary objective of this investigation was to assess the impact of acupuncture intervention and explore the intricacies of acupoint selection as a therapeutic strategy for chemotherapy-induced Anorexia (CIA).</p><p><strong>Method: </strong>Eight electronic databases were searched to identify relevant studies on the use of acupuncture for the treatment of CIA to conduct a comprehensive meta-analysis. Following this, the Apriori algorithm, correlation analysis, and cluster analysis were performed to identify correlations between the selection of acupoints.</p><p><strong>Results: </strong>Acupuncture significantly reduced the incidence of anorexia (RR = 0.76, 95%CI: 0.65, 0.90; <i>I</i><sup>2</sup>=63%; <i>p</i> = 0.001; <i>n</i> = 503) and anorexia score (SMD=-0.33, 95%CI: -0.53, -0.14; <i>I</i><sup>2</sup>=22%; <i>p</i> = 0.0008; <i>n</i> = 419), as well as preserved body mass (MD = 2.70, 95%CI: 1.08, 4.32; <i>I</i><sup>2</sup>=0%; <i>p</i> = 0.001; <i>n</i> = 187) and enhanced physical strength (MD = 4.23, 95%CI: 1.90, 6.55; <i>I</i><sup>2</sup>=58%; <i>p</i> = 0.0004; <i>n</i> = 377). Moreover, subgroup analysis highlighted its efficacy in managing anorexia associated with non-gastrointestinal tumors and mitigating the severity of cisplatin-induced anorexia. Meanwhile, Zusanli (ST36), Neiguan (PC6), Tianshu (ST25), Zhongwan (RN12), and Qihai (RN6) were identified as crucial acupoints in CIA management.</p><p><strong>Conclusion: </strong>Acupuncture holds promise as a potential non-pharmacological approach for managing anorexia during cancer chemotherapy. To provide robust evidence of its effectiveness, well-designed Randomized Controlled Trials (RCTs) with larger participant cohorts, and consistent core outcome measures are essential.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"230-243"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Serum Aflatoxin B1-Lysine Adduct Concentration and Gallbladder Cancer: A Case-Control Study.","authors":"Ratnakar Shukla, Toshikazu Ikoma, Yasuo Tsuchiya, Takao Asai, Anand Nagar, Vinay Kumar Kapoor","doi":"10.1080/01635581.2025.2475545","DOIUrl":"10.1080/01635581.2025.2475545","url":null,"abstract":"<p><p>Aflatoxin B1 (AFB1) may be associated with not only developing liver cancer but also gallbladder cancer (GBC). We aimed to investigate whether serum AFB1 level of GBC patients is higher than chronic cholecystitis (CC) patients or healthy subjects (HS). Serum was collected from 45 GBC patients (18 men, 27 women), 57 CC patients (22 men, 35 women), and 55 HS (20 men, 35 women) from May 2021 to February 2024. Serum AFB1-lysine adduct level was measured using a commercial ELISA kit. Detection frequency (≥0.1 ng/ml), median and mean levels of serum AFB1-lysine adduct were compared among three groups. The detection rate was 71% (35/45) in GBC patients, 39% (22/57) in CC, and 7% (4/55) in HS (<i>p</i> < 0.001). Age- and gender-adjusted odds ratios of AFB1 detection in GBC patients were 4.1 and 16.8 times higher than in CC patients and HS, respectively. The median levels were 5.0 ng/mL in GBC patients and < 0.1 ng/mL in CC patients and HS. The mean level in GBC patients (7.9 ± 8.4 ng/mL) was significantly higher than that in CC patients (2.7 ± 4.5 ng/mL) or HS (0.3 ± 1.1 ng/mL). Our findings show direct evidence that AFB1 exposure may be associated with risk of developing GBC in India.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"619-625"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fang Yu, Nan Yu, Lei Zhang, Xiaona Xu, Yan Zhao, Zipeng Cao, Feng Wang
{"title":"Emodin Decreases Tumor-Associated Macrophages Accumulation and Suppresses Bladder Cancer Development by Inhibiting CXCL1 Secretion from Cancer-Associated Fibroblasts.","authors":"Fang Yu, Nan Yu, Lei Zhang, Xiaona Xu, Yan Zhao, Zipeng Cao, Feng Wang","doi":"10.1080/01635581.2025.2480309","DOIUrl":"10.1080/01635581.2025.2480309","url":null,"abstract":"<p><p>Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are the most abundant stromal cells in the bladder cancer (BC) microenvironment (TME). However, the detailed mechanisms underlying TAM-CAF communication and their contributions to BC progression remain incompletely understood. Emerging evidence shows that Emodin exerts anti-tumor effect on several tumor models by targeting TME. To date, the impact of Emodin on BC has not been previously reported. Our study firstly demonstrated that Emodin significantly inhibited tumor growth and reduced TAM accumulation in a murine BC model. Emodin markedly decreased serum levels of multiple chemokines in tumor-bearing mice, with CXCL1 showing the most pronounced reduction. Strikingly, Emodin selectively suppressed CXCL1 secretion in CAFs but not in TAMs or tumor cells. Furthermore, the decrease in TAM migration induced by Emodin was dependent on CAF-derived CXCL1. Using a subcutaneous tumor model, we found that Emodin failed to inhibit tumor growth when CXCL1-deficient CAFs were co-injected with tumor cells, underscoring the critical role of CXCL1 in this process. Bioinformatics analysis further revealed that elevated CXCL1 levels correlated negatively with invasive/metastatic potential and overall survival in BC patients. In conclusion, our findings establish that Emodin delays BC progression by disrupting CXCL1-mediated crosstalk between CAFs and TAMs.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"706-721"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143671818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiwei Wang, Yong Huang, Xilan Zheng, Ming Xie, Yin Wu, Li Yang, Chunmei Yin
{"title":"Effect of Nutritional Intervention on Chemotherapy Tolerance and Quality of Life in Patients with Colorectal Cancer Undergoing Postoperative Chemotherapy: A Randomized Controlled Study.","authors":"Jiwei Wang, Yong Huang, Xilan Zheng, Ming Xie, Yin Wu, Li Yang, Chunmei Yin","doi":"10.1080/01635581.2025.2449719","DOIUrl":"10.1080/01635581.2025.2449719","url":null,"abstract":"<p><p>This study explored the effect of symptom-based individualized nutritional intervention on chemotherapy tolerance and quality of life (QOL) in patients with colorectal cancer (CRC) undergoing postoperative chemotherapy. Postoperative patients with CRC (<i>n</i> = 88) were randomly assigned to the control group (CG, <i>n</i> = 45) and intervention group (IG, <i>n</i> = 43) receiving conventional diet counseling and symptom-based individualized nutritional intervention, respectively, and chemotherapy tolerance, adverse effects, and QOL were compared. Participants in the IG exhibited better nutritional status at the last chemotherapy cycle, with lower Nutrition Risk Screening 2002 (2.37 ± 0.65 vs. 3.78 ± 0.65, <i>p</i> < 0.01) and Patient-Generated Subjective Global Assessment (6.26 ± 0.76 vs. 7.78 ± 0.70, <i>p</i> < 0.01) scores. Compared with CG, relative dose intensity reduction (9.3% vs. 25.89%, <i>p</i> = 0.02), chemotherapy regimen change (25.58% vs. 53.33%, <i>p</i> < 0.01), and chemotherapy delay (13.95% vs. 35.56%, <i>p</i> = 0.019) were lower in the IG. Nausea/vomiting (2.33% vs. 17.78%, <i>p</i> = 0.017), thrombocytopenia (2.33% vs. 28.89%, <i>p</i> < 0.01), and hand-foot syndrome (4.65% vs. 22.22%, <i>p</i> = 0.03) were less frequent in the IG. Participants in the IG had better QOL, with higher physical function scores at cycles 4 (67.91 ± 5.22 vs. 62.22 ± 4.02, <i>p</i> < 0.01) and 8 (72.71 ± 6.31 vs. 57.63 ± 4.75, <i>p</i> < 0.01). Individualized nutritional interventions improved chemotherapy tolerance and QOL and reduced adverse effects in this patient cohort.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"414-423"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexie Oppermann, Shalet James, Mackenzie M Minotti, Kaitlin M Schotz, Martha E Francis, Ian R Kleckner, Melissa A L Vyfhuis, Matthew J Ferris, Brenton J Baguley, Amber S Kleckner
{"title":"Dietary Counseling Interventions During Radiation Therapy: A Systematic Review of Feasibility, Safety, and Efficacy.","authors":"Alexie Oppermann, Shalet James, Mackenzie M Minotti, Kaitlin M Schotz, Martha E Francis, Ian R Kleckner, Melissa A L Vyfhuis, Matthew J Ferris, Brenton J Baguley, Amber S Kleckner","doi":"10.1080/01635581.2024.2406999","DOIUrl":"10.1080/01635581.2024.2406999","url":null,"abstract":"<p><p>Radiotherapy is a common cancer treatment, and concurrent nutritional interventions can maintain nutritional status and improve clinical and supportive care outcomes. However, optimal nutritional interventions during radiotherapy are not firmly established. Herein, we assessed the feasibility, safety, and efficacy of dietary counseling interventions without oral nutrition supplements on health outcomes in adults receiving radiotherapy for cancer in a systematic review. Prospective clinical trials that implemented nutritional counseling interventions during radiotherapy were identified from four databases from inception through December 2023. Feasibility, safety, and efficacy were extracted from 32 articles that described 23 randomized and 4 non-randomized clinical trials. The interventions included individualized nutritional counseling (<i>n</i> = 14 articles), nutritional counseling plus exercise (<i>n</i> = 4), and nutritional counseling focused on increasing or reducing intake of specific nutrients (<i>n</i> = 9). Trials targeted head and neck (<i>n</i> = 12), pelvic cancers (<i>n</i> = 14), and/or breast (<i>n</i> = 5) cancers. Control groups had variable designs and included general nutrition education and intervention as needed. Studies recruited 120 ± 104 participants (range 26-468). Interventions tended to be feasible regarding retention and attendance at sessions, though feasibility metrics varied among different interventions. Most interventions were safe with no studies reporting adverse events attributable to dietary intervention. Individualized dietary counseling interventions tended to lead to between-group differences favoring the intervention group in regard to improved nutritional status, maintenance or attenuation of loss of body mass, improved quality of life, and reduced radiation-induced toxicities. Diets that encouraged/discouraged specific nutrients tended to recruit patients receiving radiation to the pelvic area and resulted in positive or neutral effects on gastrointestinal symptoms. In conclusion, nutritional interventions appear to be feasible, safe, and effective during radiotherapy for various symptom outcomes.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"26-50"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142332565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Wei Li, Hai Zhu, Haizheng Dong, Bo Shi, Zhengkun Qin, Fuling Huang, Zhu Yu, Siyu Liu, Zhen Wang, Junqiang Chen
{"title":"Body Composition Decrease and Impact on Clinical Outcome in Gastric Cancer Patients Undergoing Radical Gastrectomy After Neoadjuvant Treatment.","authors":"Wei Li, Hai Zhu, Haizheng Dong, Bo Shi, Zhengkun Qin, Fuling Huang, Zhu Yu, Siyu Liu, Zhen Wang, Junqiang Chen","doi":"10.1080/01635581.2024.2418622","DOIUrl":"10.1080/01635581.2024.2418622","url":null,"abstract":"<p><p>This study investigates the impact of neoadjuvant therapy (NT) on body composition and its correlation with long-term survival and other clinical outcomes in patients with advanced gastric cancer. We utilized Computed Tomography (CT) scans to measure body composition before and after NT, including Subcutaneous Adipose Tissue Index (SATI), Visceral Adipose Tissue Index (VATI), Skeletal Muscle Index (SMI), and Muscle Density (MA). We then analyzed the decrease in body composition in relation to tumor regression, inflammatory markers, nutritional scores, and long-term survival. Our findings reveal a negative correlation between the decrease in SATI and VATI after NT, and both tumor regression and nutritional score. Notably, patients who experienced a significant loss in SATI or VATI post-NT had shorter Recurrence-Free Survival (RFS) and Overall Survival (OS). Additionally, significant loss in SATI and VATI emerged as an independent risk factor for both RFS and OS. In conclusion, our study convincingly demonstrates that in patients with advanced gastric cancer, SATI and VATI decreases after NT and is negatively associated with tumor regression and nutritional score. A significant loss in SATI and VATI is a risk factor for shorter RFS and OS, thereby underscoring the importance of maintaining body composition during NT.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"276-287"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shuyue Xiao, Xiaohui Huang, Shuer Liu, Di Jin, Zheng Liu
{"title":"Alterations of Nutrient Elements in Hepatocellular Carcinoma Patients Treated with Atezolizumab-Bevacizumab.","authors":"Shuyue Xiao, Xiaohui Huang, Shuer Liu, Di Jin, Zheng Liu","doi":"10.1080/01635581.2024.2415136","DOIUrl":"10.1080/01635581.2024.2415136","url":null,"abstract":"<p><p>Currently, the combination of atezolizumab and bevacizumab (Atez/Bev) is recommended as the first-line therapy for patients with advanced hepatocellular carcinoma (HCC). However, there is a lack of research on the levels of nutrient elements in advanced HCC patients receiving Atez/Bev treatment. In this study, data from 35 patients with advanced HCC and 37 healthy individuals of similar age and sex were included. The levels of alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were significantly increased in patients with HCC. These levels returned to the reference range after three rounds of Atez/Bev treatment. Additionally, the levels of blood urea nitrogen and creatinine (Cr) increased after Atez/Bev treatment. In HCC patients, the levels of calcium (Ca), iron (Fe), and copper (Cu) were significantly higher, while the levels of sodium (Na), magnesium (Mg), and zinc (Zn) were significantly lower compared to healthy individuals. These changes were reversed after Atez/Bev treatment. In conclusion, our findings indicate that treatment with Atez/Bev influences the levels of Ca, Fe, Cu, Na, Mg, and Zn in patients with HCC. The alterations in these elements caused by Atez/Bev treatment require mechanistic research in the future.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"244-251"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142481156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of Changes in Skeletal Muscle Mass Index on Prognosis During Alternating Chemoradiotherapy in Nasopharyngeal Carcinoma.","authors":"Mariko Ichinose, Kazuhira Endo, Nobuyuki Hirai, Eiji Kobayashi, Takayoshi Ueno, Yosuke Nakanishi, Satoru Kondo, Tomokazu Yoshizaki","doi":"10.1080/01635581.2025.2466234","DOIUrl":"10.1080/01635581.2025.2466234","url":null,"abstract":"<p><p>Sarcopenia is common in patients with head and neck cancer and is suggested to be associated with decreased survival. This study aimed to investigate the relationship between changes in skeletal muscle mass during alternating chemoradiotherapy (CRT) and the prognosis of patients with nasopharyngeal carcinoma (NPC). This retrospective study included 64 patients with NPC who had undergone alternating CRT at our institution between 2005 and 2022. The skeletal muscle mass index (SMI) was measured using pre- and post-treatment computed tomography. SMI decreased in 58 patients (90.6%), with a mean change of -6.1%. Using a cutoff value of -6.0% for SMI change, 32 patients (50.0%) were categorized into the SMI loss group. The SMI loss group had a significantly lower mean overall survival (OS) than the SMI maintenance group (122.6 vs. 153.0 months; <i>p</i> = 0.021). Multivariate analysis identified SMI loss and prognostic nutritional index (PNI) as independent predictors of poor OS (<i>p</i> < 0.05). They were used to construct the nomogram of OS. In conclusion, SMI loss during alternating CRT was identified as a poor prognostic factor. These findings suggest that preserving skeletal muscle mass during alternating CRT may improve the prognosis and merits further investigation.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"444-454"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143450781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paola Sanches Cella, Ricardo Luís Nascimento de Matos, Poliana Camila Marinello, T A S Guimarães, J H C Nunes, Felipe Arruda Moura, Ana Paula Frederico Rodrigues Loureiro Bracarense, Patrícia Chimin, Rafael Deminice
{"title":"Creatine Supplementation Mitigates Doxorubicin-Induced Skeletal Muscle Dysfunction but Not Cardiotoxicity.","authors":"Paola Sanches Cella, Ricardo Luís Nascimento de Matos, Poliana Camila Marinello, T A S Guimarães, J H C Nunes, Felipe Arruda Moura, Ana Paula Frederico Rodrigues Loureiro Bracarense, Patrícia Chimin, Rafael Deminice","doi":"10.1080/01635581.2025.2461257","DOIUrl":"10.1080/01635581.2025.2461257","url":null,"abstract":"<p><p>Creatine has demosntrated protective effects against muscle dysfunction, but its potential protection against doxorubicin-induced cardio and skeletal muscle toxicity remains poorly understood. We aimed to investigate the protective effects of creatine supplementation against doxorubicin-induced cardio and skeletal muscle myotoxicity. This study analyzed twenty male C57BL/6J mice, divided into three groups: Control (C; <i>n</i> = 6), Dox (<i>n</i> = 7) which received weekly doxorubicin injections (16 mg/kg i.p. in 20 days) and DoxCr (<i>n</i> = 7) with both doxorubicin and creatine supplementation (4%). Doxorubicin administration induced skeletal muscle atrophy in extensor digitorum longus (EDL) (-28%) and soleus muscles (-17%), accompanied by a decline in muscle strength. This atrophic response was concomitant with increased oxidative stress and elevated levels of IL-6. Cardiotoxic effects of doxorubicin were marked by a 15% reduction in cardiac mass and a significant 21% decrease in cardiomyocyte diameter, alongside a substantial 58% rise in IL-6 levels. On the opposite creatine supplementation mitigated doxorubicin-induced oxidative stress (elevated MDA and IL-6, and reduced GSH/GSSG ratio) and prevented skeletal muscle atrophy in both the EDL and soleus muscles, while also enhancing muscle strength. However, protective effects were not observed in cardiac muscle. Creatine protects skeletal, but not cardiac muscle against doxorubicin-induced toxicity, atrophy and strength loss.</p>","PeriodicalId":54701,"journal":{"name":"Nutrition and Cancer-An International Journal","volume":" ","pages":"506-517"},"PeriodicalIF":2.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}